Investment Rating - The industry investment rating is "Positive" (首次) [1] Core Insights - The beauty and personal care industry is experiencing a mixed performance, with the beauty care index declining by 1.70% in December 2025, ranking 24th among all primary industries [15] - The medical beauty sector is seeing innovation with the approval of new products, such as the cross-linked recombinant collagen implant by Jiangsu Chuangjian Medical Technology Co., which is expected to inject new momentum into the market [7][34] - Lin Qingxuan, a pioneer in the "oil-based skincare" segment, has successfully listed on the Hong Kong Stock Exchange, marking a significant milestone for domestic high-end skincare brands [8][39] Summary by Sections Market Review - In December, the beauty care index reported a decline of 1.70%, underperforming the broader market, which saw the Shanghai Composite Index increase by 2.06% [15] - For the entire year of 2025, the beauty care index showed a cumulative increase of 0.39%, again lagging behind the Shanghai Composite Index's 18.41% growth [15] Medical Beauty - Jiangsu Chuangjian Medical's cross-linked recombinant collagen implant has been approved, making it the fifth such product in China and the first cross-linked version [34] - The industry is shifting from single product competition to a full-chain layout, with companies like Jinjian Biological and Junzi Biological also making significant advancements in the recombinant collagen space [34][36] Cosmetics - Lin Qingxuan has established itself as a leader in the high-end domestic skincare market, achieving the highest retail sales among domestic brands in 2024 [39] - The company has built a comprehensive supply chain and employs an OMO (Online-Merge-Offline) model to enhance customer engagement and sales [39][49] - Lin Qingxuan's core product, the camellia oil essence, has a high repurchase rate of 33.5%, indicating strong customer loyalty [51] Investment Recommendations - The report recommends focusing on differentiated upstream medical beauty product manufacturers and chain medical beauty institutions, highlighting companies like Meili Tianyuan Medical Health and Aimeike [9][53] - In cosmetics, the report suggests investing in brands that innovate in emotional value and safe ingredients, with a focus on domestic brands like Maogeping and Lin Qingxuan [54]

巨子生物回购明细 | 日期 | 回购股数（万股） | 回购最高价（港元） | 回购最低价（港元） | 回购金额（万港元） | | --- | --- | --- | --- | --- | | 2026.01.09 | 40.00 | 34.580 | 34.240 | 1375.96 | | 2026.01.08 | 40.00 | 34.440 | 34.120 | 1371.06 | | 2026.01.07 | 40.00 | 34.680 | 34.300 | 1378.34 | | 2026.01.06 | 40.00 | 34.480 | 33.840 | 1366.93 | | 2026.01.05 | 40.00 | 34.280 | 33.740 | 1358.16 | （文章来源：证券时报网） 证券时报·数据宝统计，巨子生物在港交所公告显示，1月9日以每股34.240港元至34.580港元的价格回购 40.00万股，回购金额达1375.96万港元。该股当日收盘价34.420港元，上涨0.06%，全天成交额1.09亿港 元。 自1月5日以来公司已连续5日进行回购，合计回购200.00万股， ...

格隆汇1月9日丨巨子生物(02367.HK)公告，1月9日耗资1376万港元回购40万股，每股回购价34.24-34.58 港元。 ...

巨子生物(02367)发布公告，于2026年1月9日该公司斥资1375.96万港元回购40万股，回购价格为每股 34.24-34.58港元。 ...

智通财经APP讯，巨子生物(02367)发布公告，于2026年1月9日该公司斥资1375.96万港元回购40万股， 回购价格为每股34.24-34.58港元。 ...

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 巨子生物控股有限公司 呈交日期： 2026年1月9日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 02367 | 說明 | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | | | | | 事件 | 已發行股份（不包括庫存股份）數 目 | | 佔有關事 ...

Market Performance - The Hong Kong stock market experienced a mixed performance with the Hang Seng Index rising by 82.48 points, or 0.32%, closing at 26,231.79 points [1] - The Hang Seng Tech Index increased by 8.8 points, or 0.15%, to 5,687.14 points, while the China Enterprises Index rose by 9.19 points, or 0.1%, to 9,048.53 points [1] - Major tech stocks showed varied movements, with Alibaba up 2.73%, Tencent down 0.81%, and JD.com up 2.6% [1] Company News - Fast Retailing (迅销) reported a revenue of 1,027.745 billion yen for the first quarter ending November 30, 2025, a year-on-year increase of 14.8%, and a net profit of 147.445 billion yen, up 11.7% year-on-year [2] - Baidu Cloud (百融云) repurchased 4.15 million shares for a total of 51.783 million HKD at a price range of 12.41-12.51 HKD [3] - Tencent Holdings (腾讯控股) repurchased 1.636 billion HKD worth of shares, buying back 1.034 million shares at a price range of 610.5-618.5 HKD [4] - Xiaomi Group (小米集团) repurchased 5 million shares for 191 million HKD at a price range of 38.04-38.16 HKD [5] - Vanke Enterprises (万科企业) announced the retirement of Yu Liang, who stepped down from his roles as director and executive vice president [7] Industry Insights - CITIC Securities forecasts that the Hong Kong stock market may see a second round of valuation recovery and performance revival in 2026, driven by internal and external economic factors [13] -招商证券 suggests that the market will enter a phase of structural differentiation, focusing on quality-driven growth, and recommends a dual strategy of focusing on both rebound opportunities and growth stocks [13] - Zheshang International maintains a cautiously optimistic outlook for the Hong Kong market, highlighting sectors benefiting from policy support such as new energy, innovative pharmaceuticals, and AI technology [14]

Core Viewpoint - The recent announcement of share reduction by Maogeping Company, a leading domestic high-end cosmetics brand, has attracted significant market attention, highlighting the wealth and financial strategies of its founders, Maogeping and his family [2][3]. Group 1: Company Overview - Maogeping Company, listed on the Hong Kong Stock Exchange, has a market capitalization of HKD 42.25 billion as of January 8, 2024, with projected revenue exceeding HKD 3.8 billion for the year [2]. - The company was founded in 2000 by Maogeping, who transitioned from a film makeup artist to a prominent figure in the beauty industry [2]. Group 2: Wealth and Shareholding Structure - Maogeping and his spouse, Wang Liqiong, have a combined wealth of RMB 12.5 billion, ranking them 2188th on the 2025 Hurun Global Rich List [3][4]. - The family holds a significant portion of the company's shares, with Maogeping and Wang Liqiong owning approximately 29.22% of the equity, while other family members collectively hold over 50% [5][6]. Group 3: Financial Performance - The company has experienced rapid growth since 2021, with a compound annual growth rate (CAGR) of 35.04% in revenue and 38.56% in net profit, significantly outpacing industry averages [9]. - Revenue figures from 2021 to 2024 show a consistent upward trend, with revenues increasing from RMB 1.577 billion in 2021 to RMB 3.885 billion in 2024, and net profit rising from RMB 331 million to RMB 881 million [9][10]. - In the first half of 2025, the company reported revenues of RMB 2.588 billion and a net profit of RMB 670 million, reflecting year-on-year growth rates of 31.3% and 36.1%, respectively [9][10]. Group 4: Product and Market Position - Maogeping's flagship brand contributes over 99% of the company's revenue, with a diverse product range that includes over 400 items across makeup, skincare, and fragrance categories [10][11]. - The company maintains a high gross margin, consistently above 83%, which is significantly higher than competitors like Proya and Shanghai Jahwa [9][10]. - Notable products include the "Luxury Caviar Cushion" and "Light Sense Soft Color Powder Cake," each generating over RMB 200 million in retail sales in the first half of 2025 [13]. Group 5: Future Prospects - The company is expected to continue its growth trajectory with plans to expand into new markets and product lines, including fragrances, supported by the establishment of a new R&D center in Hangzhou [10]. - As of October 2025, the family's wealth has reportedly increased to RMB 20.5 billion, indicating a successful financial strategy and business expansion [10].

Market Overview - The Hong Kong stock market opened higher but experienced a downward trend, with the Hang Seng Index up 0.03% at 26,158.21 points, the Hang Seng Tech Index down 0.06% at 5,674.78 points, and the National Enterprises Index up 0.04% at 9,042.8 points [1] - Major tech stocks showed mixed performance, with Alibaba up 2.81%, Tencent down 0.73%, JD.com up 2.95%, Xiaomi down 0.42%, NetEase down 1.64%, Meituan down 2.38%, Kuaishou up 2.85%, and Bilibili up 3.32% [1] - The commercial aerospace sector was strong, with Asia Pacific Satellite rising over 15%, while gold stocks saw gains, with Shandong Gold up over 6% [1] - Solar energy stocks weakened, with GCL-Poly Energy down over 8%, and real estate and aviation stocks showed collective weakness [1] - MiniMax, a large model enterprise, saw its stock rise over 78% on its first trading day, reaching 294 HKD [1] Company News - Fast Retailing (迅销) reported Q1 earnings for the period ending November 30, 2025, with revenue of 1,027.745 billion JPY, a year-on-year increase of 14.8%, and net profit of 147.445 billion JPY, up 11.7% year-on-year [2] - Bairong Cloud (百融云) repurchased 4.15 million shares for 51.783 million HKD at a price range of 12.41-12.51 HKD [3] - Xianjian Technology (先健科技) received formal registration approval from the National Medical Products Administration for its G-iliacTM Pro iliac artery stent system [4] - Tencent Holdings (腾讯控股) repurchased 1.036 million shares for 636 million HKD at a price range of 610.5-618.5 HKD [4] - Xiaomi Group (小米集团) repurchased 5 million shares for 191 million HKD at a price range of 38.04-38.16 HKD [5] - Giant Bio (巨子生物) repurchased 400,000 shares for 13.7106 million HKD at a price range of 34.12-34.44 HKD [6] - Vanke Enterprises (万科企业) announced the resignation of Yu Liang due to retirement [7] - Baolong Real Estate (宝龙地产) reported a total contract sales amount of approximately 7.272 billion CNY for 2025, a year-on-year decrease of 43.13% [8] - China General Nuclear Power (中广核电力) projected a total on-grid electricity of approximately 2,326.48 billion kWh for 2025, a year-on-year increase of 2.36% [9] - Jieli Trading Treasure (捷利交易宝) reported an increase of 7 institutional clients in December 2025, a year-on-year increase of 1, with registered users at approximately 886,700, up 6.2% year-on-year [9] - CWT International (CWT INT'L) signed a memorandum of cooperation with SF Express Singapore to jointly build a one-stop local and international logistics service [10] - Merui Health International (美瑞健康国际) plans to acquire 100% equity of Jiangsu Yide for 125 million CNY [11] - Dimi Life Holdings (迪米生活控股) entered into a strategic cooperation framework agreement with partners to enter the electronic vaporization industry [12] Institutional Insights - Everbright Securities indicated that domestic policy support combined with a weaker US dollar may lead to continued upward movement in the Hong Kong stock market, highlighting strong overall profitability and the relative scarcity of assets in internet, new consumption, and innovative pharmaceuticals [13] - Galaxy Securities expects active trading in the Hong Kong market to persist due to multiple positive factors, projecting an overall upward trend [13] - Dongwu Securities noted that the Hong Kong market is entering a period of upward fluctuation, emphasizing the importance of dividends as a base and the potential for technology growth in the first half of the year [13]

Market Overview - The Hong Kong stock market opened higher on January 9, with the Hang Seng Index rising by 0.47% to 26,272.54 points, the Hang Seng Tech Index increasing by 0.38% to 5,699.97 points, the State-Owned Enterprises Index up by 0.35% to 9,070.91 points, and the Red Chip Index gaining 0.45% to 4,112.86 points [1] - Major technology stocks saw positive movement, with Alibaba up 3.79%, JD Group up 3.31%, and Bilibili up 2.95%. However, Meituan and Kuaishou experienced declines of 0.99% and 0.90%, respectively [1] - Oil stocks generally rose, with PetroChina increasing by over 1%. Chinese brokerage stocks were active, with Dongfang Securities rising by nearly 1% [1] - The biopharmaceutical sector saw a pullback, with BeiGene down over 3% [1] - Three new stocks were listed today, all opening higher: Reborn Bio-B surged over 29%, MINIMAX soared over 42%, and Jinxun Resources rose over 26% [1] Company News - Fast Retailing (06288.HK) reported first-quarter earnings for the period ending November 30, 2025, with revenue of 1,027.745 billion yen, a year-on-year increase of 14.8%, and net profit of 147.445 billion yen, up 11.7% year-on-year [2] - Vanke Enterprises (02202.HK) announced that Yu Liang has resigned from his positions as director and executive vice president due to retirement [3] - Baolong Real Estate (01238.HK) projected a total contract sales amount of approximately 7.272 billion yuan for 2025, a year-on-year decrease of 43.13% [4] - China General Nuclear Power (01816.HK) expects a total on-grid electricity of approximately 2,326.48 billion kilowatt-hours for 2025, a year-on-year increase of 2.36% [4] - Meirui Health International (02327.HK) plans to acquire 100% equity of Jiangsu Yide for 125 million yuan [5] Strategic Developments - CWT International (00521.HK) has formalized a memorandum of cooperation with SF Express Singapore to jointly build a one-stop local and international logistics service [6] - Dimy Life Holdings (01667.HK) has entered into a strategic cooperation framework agreement with partners to venture into the electronic vaporization industry [7] - Xianjian Technology (01302) received formal registration approval from the National Medical Products Administration for its G-iliacTM Pro iliac artery stent system [8] Stock Buybacks - Tencent Holdings (00700.HK) repurchased 1.034 million shares for 636 million HKD at prices ranging from 610.5 to 618.5 HKD [8] - Xiaomi Group (01810.HK) repurchased 5 million shares for 191 million HKD at prices between 38.04 and 38.16 HKD [9] - Bairong Cloud (06608.HK) repurchased 415,000 shares for 51.783 million HKD at prices between 12.41 and 12.51 HKD [10] - Juzhi Biotechnology (02367.HK) repurchased 40,000 shares for 13.7106 million HKD at prices between 34.12 and 34.44 HKD [11] Institutional Insights - Everbright Securities suggests that domestic policy initiatives combined with a weaker US dollar may lead to continued upward movement in the Hong Kong stock market, highlighting strong overall profitability and relatively low valuations [12] - Dongwu Securities anticipates significant catalysts for the commercial aerospace industry in 2026, particularly with the launch of multiple reusable and large-capacity commercial rockets [12] - Kaiyuan Securities notes a "dual-drive" investment logic in semiconductor materials and equipment, driven by supply chain security concerns and recent capital investments in domestic manufacturing [12]